Procedure Restores Pigmentation for Patients With Vitiligo
The melanocyte-keratinocyte transplantation procedure (MKTP) is well tolerated and is effective for restoring skin pigmentation for some patients with vitiligo.
Dermatological Disorders
Head Lice Beginning to Show Permethrin Resistance
Although live head lice obtained from school-aged children in Paris remain susceptible to the insecticide malathion, approximately 14% have been found to be resistant to permethrin, suggesting a strong basis for future insecticide resistance.
Phase 3 Trial of POL 103A Vaccine for Melanoma
Polynoma LLC announced the start of MAVIS, the company’s Phase 3 trial of POL 103A vaccine for melanoma.
Acellular Dermal Matrix Safe, Useful in Breast Reconstruction
Acellular dermal matrices provide good outcomes for patients undergoing breast reconstruction following mastectomy, but the human AlloDerm matrix has a higher seroma rate than porcine Strattice matrix.
Skin Testing Not Sufficient to ID Contrast Media Sensitivity
More than 50% of patients with nonimmediate reactions to iodinated contrast media (CM) are identified with the drug provocation test (DPT) and not with skin testing.
Acne Medication Isotretinoin Increases Risk of Eye Disorders
The acne medicine isotretinoin may be linked to a nearly two-fold increased risk of ocular adverse effects in users.
Common Therapies for Basal Cell Carcinoma Offer Similar Survival
For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival.
Vigorous Physical Activity Tied to Reduced Psoriasis Risk
Vigorous physical activity is associated with a reduced risk of psoriasis in women.
Epidemiology of Rosacea Described in United Kingdom
The incidence of rosacea in the United Kingdom is 1.65 per 1,000 person-years, with alcohol consumption linked to a modest increase in risk and current smoking linked to an decreased risk.
Fabior Foam, 0.1% Approved for Acne Vulgaris
Stiefel has received FDA approval for Fabior Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years of age and older.
